Germany
· Delayed Price · Currency is EUR Pharming Group Company Description
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE.
It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105.
Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
| Country | Netherlands |
| Founded | 1988 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 404 |
| CEO | Fabrice Chouraqui |
Contact Details
Address: Darwinweg 24 Leiden, 2333 CR Netherlands | |
| Phone | 31 71 524 7400 |
| Website | pharming.com |
Stock Details
| Ticker Symbol | PHGN |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Fabrice Chouraqui | Chief Executive Officer |
| Kenneth Lynard | Chief Financial Officer |
| Mireille Sanders | Chief Operating Officer |
| Susanne Embleton | Head of Investor Relations |